Showing results (141-150 of 179) with videos related to

Sort By:
Pageof 18
Clinical Lung Cancer|January 19, 2025
Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket TrialJonathan W Goldman, Alejandro Martinez Bueno, Christophe Dooms, et al.
The Lancet. Gastroenterology & Hepatology|December 5, 2025
Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trialMilind Javle, Christos Fountzilas, Chih-Yi Liao, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|May 5, 2024
Neoadjuvant therapy leads to objective response in intrahepatic cholangiocarcinomaBenjamin J Van Treeck, Maria C Olave, Ryan D Watkins, et al.
Practical Radiation Oncology|July 27, 2020
Patient-Reported Quality of Life Before and After Chemoradiation for Intact Pancreas Cancer: A Prospective Registry StudyWilliam G Breen, Krishan R Jethwa, Nathan Y Yu, et al.
Cancer Management and Research|December 20, 2019
First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced MalignancyPamela Munster, Monica Mita, Amit Mahipal, et al.
Investigational New Drugs|August 31, 2021
A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinomaDaniel H Ahn, Pedro Luiz Serrano Uson Junior, Peter Masci, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|May 24, 2024
WITHDRAWN: Neoadjuvant therapy leads to objective response in intrahepatic cholangiocarcinomaBenjamin J Van Treeck, Maria C Olave, Ryan D Watkins, et al.
The Oncologist|June 20, 2023
Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract CarcinomaSri Harsha Tella, Nathan Foster, Shi Qian, et al.
The Oncologist|December 14, 2024
Second-line therapies in advanced hepatocellular carcinoma following first-line atezolizumab and bevacizumab: multicenter single institution cohort experiencePaulina Marell, Ioannis Kournoutas, Jennifer Gile, et al.
Journal for Immunotherapy of Cancer|March 14, 2024
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trialHeinz-Josef Lenz, Aparna Parikh, David R Spigel, et al.
Pageof 18